Blons, 2004 | MMP-1 (1607insG), MMP-3 (1612insA), MMP-7 (181A3G, 153C3T) | Tissue remodeling gene | Neoadjuvant Chemotherapy (cisplatin, 5-fluorouracil | Oral cavity, oropharynx, hypopharynx, larynx | 148 |
Kimura, 2004 | GSTP1(I105V) | Antioxidant and drug detoxification genes | Chemotherapy (cisplatin) | HNSCC Cell lines | 17 |
Quintela-Fandino, 2006 | XPD (Asp312Asn, Lys751Gln), ERCC1 (C8092A), XRCC1 (Arg399Gln) | DNA-repair gene | Induction chemotherapy (cisplatin) | Nasopharynx, oral cavity, oropharynx, hypopharynx, larynx, lip | 103 |
Alsbeih, 2008 | XRCC1( 399 G>A Arg/Gln), XRCC3 (241 C>T Thr/Met) | DNA-repair gene | Radiotherapy | Nasopharynx | 50 |
Werbrouck, 2009 | XRCC3 (c.-1843A>G, c.562–14A>G, c.722C>T), Rad51 (c.-3429G>C, c.-3392G>T), Lig4 (c.26C>T, c.1704T>C), Ku70 (c.-1310C>G), and Ku80 (c.2110–2408G>A) | DNA-repair gene | Radiotherapy, chemoradiotherapy, radiotherapy + surgery, chemoradiotherapy + surgery | Oral cavity, oropharynx, hypopharynx, larynx, neck | 88 |
Ansell, 2009 | FGFR4 (Gly/Arg) | Growth control | Radiation and cisplatin | HNSCC Cell lines | 39 |
Farnebo, 2009 | p53 (p5372), MDM2 (MDM2309), FGFR4 (FGFR4388), XPC (XPC499), XPD (XPD751), XRCC1 (XRCC1399), and XRCC3 (XRCC3241) | Apoptosis, Growth control, DNA-repair gene | Chemotherapy (cisplatin) | HNSCC Cell lines | 39 |
Taylor, 2009 | FcγRIIIa | Antibody-dependent cellular cytotoxicity | Targeted therapy (Cetuximab[anti-EGFR]) | HNSCC Cell lines | 3 |
Klinghammer, 2010 | EGFR (EGFR-R521Kand CA-SSR) | Growth control | Targeted therapy +Chemotherapy (cetuximab/docetaxel) | recurrent or metastatic HNSCC | 51 |
Pratesi, 2011 | XRCC1 (c.1196A > G), XRCC3 (c.722C > T), RAD51 (c.-3429G > C, c.-3392G > T) GSTP1 (c.313A > G) | DNA-Repair Gene Antioxidant and drug detoxification genes | chemo-radiotherapy and radiotherapy alone | nasopharynx, oropharynx, oral cavity, hypopharynx , larynx, sinuses, salivary glands | 101 |
Ruwali,2011 | GSTM1(null/positive), GSTT1(null/positive), GSTP1(IIe/Val) | Antioxidant and drug detoxification genes | Chemotherapy, chemoradiotherapy | oral cavity, larynx, pharynx | 500 |
Ziliak, 2011 | ACSL6 (rs6870861, rs2551038) | Fatty acid biosynthesis | Induction chemotherapy (carboplatin-based) | Head and neck cancers | 60 |
Shukla, 2012 | CYP2D6 | Drug-metabolizing enzymes | Cisplatin-based Chemoradiotherapy | oral cavity, oropharynx, the hypopharynx, and the larynx | 100 |
Venkatesh, 2014 | XRCC1 (rs25487, rs1799782, rs25489, rs3213245), XRCC3 (rs861539), XRCC4 (rs1805377), XRCC5 or Ku80 (rs3835), XRCC6 or Ku70 (rs2267437), LIG4 (rs1805388), NBN (rs1805794, rs1805787), RAD51 (rs1801320, rs1801321), ATM (rs3218698), OGG1 (rs1052133), TGFβ1 (rs1800469), CAT (rs7943316), SOD2 (rs4880), NQO1(rs1131341),GSTP1 (rs1695), GSTT1 (Present/Null), GSTM1 (Present/Null) | DNA damage and repair genes, Profibrotic and inflammatory cytokine, Antioxidant and drug detoxification genes | Platinum based chemoradiotherapy or radiotherapy alone | Hypopharynx, Oropharynx, Nasopharynx, Larynx, Oral cavity, Para nasal region, Parotid | 183 |
Pickhard, 2014 | Aurora kinase A (AurkA/STK15 Phe31Ile) | Cell proliferation | Targeted therapy (cetuximab) | Cell lines | 6 |
Pfisterer, 2015 | AKT1 (rs2494738, rs2498804, rs3803304), AKT2 (rs892119, rs8100018), FRAP1 (rs11121704, rs2295080), PIK3CA (rs2699887, rs7640662), and PTEN (rs12569998, rs2299939) | Cell proliferation | Targeted therapy +Chemotherapy (cetuximab-docetaxel) | Recurrent or initially metastatic HNSCC (oral cavity, oropharynx, the hypopharynx) | 45 |
Danielsson, 2015 | OGG1 (rs1052133), MTH1/NUDT1 (rs4866), CAT (rs1001179), SOD2A (rs4880), NOS3 (rs1799983), GSTP1 (rs1695), GSTA1 (rs3957356), NFE2L2 (rs1806649) | Antioxidant and drug detoxification genes | Radiotherapy alone, radiotherapy + brachytherapy, radiotherapy + chemotherapy | HNSCC with osteoradionecrosis( Tonsil, Tongue, other) | 37 |
Fernández-Mateos, 2016 | EGFR (rs2227983,rs28384375, rs17336639), CCDN1, FCGR2A (rs1801274), FCGR3A (rs396991), KRAS-LCS6 (rs61764370) | Growth control | chemotherapy and radiotherapy plus cetuximab (targeted therapy) | Larynx, Oropharynx, Hypopharynx, Oral cavity | 110 |
Braig, 2017 | EGFR (EGFR-K521) | Growth control | cetuximab (targeted therapy) | HNSCC Cell lines | 14 |
Lopes-Aguiar, 2017 | XPC (c.2815A>C), XPD (c.934G>A), XPD (c.2251A>C), XPF (c.2505T>C), ERCC1 (c.354C>T) | DNA-repair gene | Cisplatin-based chemoradiotherapy | Oral cavity, Pharynx, Larynx | 90 |
Baumann, 2018 | Aurora-Kinase A (Phe31-Ile) | Cell proliferation | radiation + Docetaxel (chemotherapeutic agent) + Aurora-Kinase inhibitor (targeted therapy) | HNSCC cell lines | 2 |
Nanda, 2018 | XRCC-1 (Arg194Trp) | DNA-repair gene | Concurrent chemoradiotherapy | oral cavity, hypopharynx, oropharynx, larynx | 101 |
Nogueira, 2018 | MLH1 (c.-93G>A; rs1800734), MSH2 (c.211+9C>G; rs2303426), MSH3 (c.3133G>A; rs26279), EXO1 (c.1765G>A; rs1047840), EXO1 (c.2270C>T; rs9350), | DNA-repair gene | Chemotherapy (cisplatin)+ radiotherapy | oral cavity, pharynx, larynx | 90 |
Wang, 2020 | ERCC1 (rs11615, rs3212948, rs3212961, rs735482) | DNA-repair gene | Chemotherapy | oral cavity | 113 |
Tejasvi, 2020 | ERCC1 (rs11615, rs3212986) | DNA-repair gene | Chemotherapy (cisplatin) | oral cavity | 150 |